Hormones, Blood Products, and Therapeutic Enzymes

Silva, Ana Catarina; Costa, Cynthia Hernandes; Almeida, Hugo; Moreira, João Nuno; Lobo, José Manuel Sousa

doi:10.1007/10_2019_111

Cited by 4 publications

(2 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 2019 coronavirus disease (COVID-19) pandemic is a public health concern that has not only led to high morbidity and mortality in the populations, but has negatively affected the global economy [ 1 , 2 ]. The health and economic burden caused by this pandemic therefore calls for an urgent launch of effective measures against SARS- CoV-2 [ 2 ], with the aim of ending the pandemic, or reducing its intensity on the economy and disease severity in the populations [ 3 , 4 ]. The spike protein has been demonstrated to be the most effective SARS-CoV-2 antigen and is thought to be the crucial target for SARS-CoV-2 vaccines [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide

Celise¹,

Kimotho

Kimani

et al. 2022

Vaccines

View full text Add to dashboard Cite

The effects of cytosine phosphoguanine oligodeoxynucleotides (CPG ODNs) on immune response have been demonstrated for different vaccines; however, such information is limited for the vector-based Coronavirus disease 2019 (COVID-19). This paper aims to demonstrate the potential effect of CPG ODNs on immunological response against the vector-based COVID-19 vaccine on Balb/c mice using a JNJ-78436735 Ad26.COV2-S recombinant as a model vaccine. A total of 18 BALB/c mice clustered into six groups were used. All groups were observed for 14- and 28-days post immunization. Qualitative determination of IgG was performed using indirect Enzyme-Linked Immunosorbent Assay (ELISA) and qPCR for cytokine profiling. A significant (p ≤ 0.001) rise in antibody response was observed for groups 3 and 4, who also showed increased expression levels of Tumor Necrosis Factor (TNF) and Interferon Gamma (IFN-γ). Immunological parameters for toxicity were normal in all treatment groups. We conclude that supplementing vector-based COVID-19 vaccines with CpG ODNs has the potential to boost the body’s immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide

Celise¹,

Kimotho

Kimani

et al. 2022

Vaccines

View full text Add to dashboard Cite

show abstract

“…These nanocarriers should have high transfection capabilities (in the absence of toxicity) and a synergistic drug payload [ 21 ]. In order to deliver nucleic acids successfully, such nanomedicines should overcome the intracellular barriers, including endo-lysosomal degradation, and, in the case of plasmid DNA, they should also cross the nuclear membrane [ 22 ]. In order to avoid unwanted interactions between the chemotherapeutics and nucleic acids, loading within the nanocarrier is done sequentially (usually drugs first, followed by the nucleic acid), even if some studies describe a co-loading strategy using dedicated precautions [ 14 ].…”

Section: Advantages and Challenges Of Combined Nanomedicinesmentioning

confidence: 99%

Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications

et al. 2023

View full text Add to dashboard Cite

The most important limitations of chemotherapeutic agents are severe side effects and the development of multi-drug resistance. Recently, the clinical successes achieved with immunotherapy have revolutionized the treatment of several advanced-stage malignancies, but most patients do not respond and many of them develop immune-related adverse events. Loading synergistic combinations of different anti-tumor drugs in nanocarriers may enhance their efficacy and reduce life-threatening toxicities. Thereafter, nanomedicines may synergize with pharmacological, immunological, and physical combined treatments, and should be increasingly integrated in multimodal combination therapy regimens. The goal of this manuscript is to provide better understanding and key considerations for developing new combined nanomedicines and nanotheranostics. We will clarify the potential of combined nanomedicine strategies that are designed to target different steps of the cancer growth as well as its microenvironment and immunity interactions. Moreover, we will describe relevant experiments in animal models and discuss issues raised by translation in the human setting.

show abstract

Classes of Biologicals

Silva

2024

SpringerBriefs in Molecular Science

View full text Add to dashboard Cite

Hormones, Blood Products, and Therapeutic Enzymes

Cited by 4 publications

References 85 publications

Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide

Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide

Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications

Classes of Biologicals

Contact Info

Product

Resources

About